ArticleFrontiers in public health2024
Financial assessment and diagnosis of abnormal data of listed companies in public health and wellness industry.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Corporate climate risk and public health disclosure: does digital transformation matter?Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, the present status of the public health and wellness sector in China is examined. The main objective is to evaluate the financial risk among publicly listed companies in the sector. Despite the significant expansion of the industry, research in this domain remains limited. Moreover, it frequently lacks depth, especially when it comes to financial studies designed especially for publicly traded companies. Current models for assessing corporate financial risk are frequently applied in diverse industries without necessary adjustments. Therefore, this study examines the financial performance and operational health of five publicly listed anonymized companies between 2020 and 2023. Using an efficient methodology that includes reliable data collection and quality assurance, we analyze key performance indicators such as annual revenues, liquidity ratios, and debt-to-equity ratios to assess financial stability and growth potential. Our findings reveal varied revenue trends shaped by external market shocks such as the COVID-19 pandemic. These trends highlight both the resilience of the sector and its vulnerabilities. To evaluate potential financial risks and outliers, the abnormal revenue patterns are also identified using Z-score. Benchmarking is also conducted using industry averages which provides a clearer understanding of competitive positioning. Several suggestions are made in light of the analysis to manage debt, increase liquidity, and leverage digital transformation for long-term growth. Several future directions are also presented to continue research in the domain. Overall, this study offers valuable information for stakeholders navigating the complexities of the public health and wellness industry in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.